{"name":"Endogena Therapeutics, Inc","slug":"endogena-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2025-06-26","type":"pipeline","source":"GlobeNewswire","summary":"Retinitis Pigmentosa Research Report 2025: $25+ Bn Market - GlobeNewswire","headline":"Retinitis Pigmentosa Research Report 2025: $25+ Bn Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQWm5pN3F3Wi1BVzV6eDFuX0FmcDFBV1g4Z3p5Mk5qWUc3SXdiaERQR2I0TlZTTUFSdmF1SlBNbFB4cXNOdzhhbm9ycXkzeEZpNGZVbEdEWDAtR25ZdVQ4bU43bE10SF8zYWh2VGhMbllWX0loTmpMdUsxZXMzQ0pxWHlSQ1hmWDRLNm4zRTQ3bWNHbG1RUkpwU1B3SlNqeVlCeXdwMDMyQ3hkVlVQbnBJV2lKZmRyYXoxckRZaS1FRGkwYnIyNEtCYTBXUHA4azhnS3pXWk5tUFB5dzFRdFRrTEE1T2JDMzJrX3c?oc=5","date":"2025-03-26","type":"pipeline","source":"PR Newswire","summary":"LUXTURNA Continues to Lead in Retinal Gene Therapy with Increased Market Penetration | DelveInsight - PR Newswire","headline":"LUXTURNA Continues to Lead in Retinal Gene Therapy with Increased Market Penetration | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxQbVladVBMRXRrZzAydEx1bWR0bURJeXBCbFh4UkJHb1ZZX1JYa3NzWlpSRGFvUnpXWVM4cmtoR25QQXR2TGlKTjhfTjY3NlZON0tyUVBxYy16MVJMcGdlLWFaUUJ3eVE1c2Rid1ZQc2NmbnMzdmRDTldxb2hCZmsyOUw2Ti1UMy1iNVlBbGpFWF9qeTJvMnQwQm9YRnBVOXFBeWE3c2ZoaC00M1o2WnBMQm1ZRGMxUExVdUw2WFRiMHBzc0xNMU40c3VFX3QtU291X1NnQmlkYTVrX1YyX3R6RkdBZFo5RzU4Z0ZXUzBILWtGcmJXbU4ydVJnTklzOC0tS3ZfTFloWWdfNm9wcFdMVWhaRmJ2VE1IdXgzUzh2cjAzS1Y1?oc=5","date":"2025-02-21","type":"pipeline","source":"GlobeNewswire","summary":"Cell and Gene Therapies in Rare Disorders Market to - GlobeNewswire","headline":"Cell and Gene Therapies in Rare Disorders Market to","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxOWnFwcEFyaWluNXNacFJfeWQ2NVdsUjEzRG1YeS1TWDUzQ01vYzBtN1lSOHNZMGRjREktdEdBOWV6U2l6QUwtLTI0MVFpekxyTFM0NDZVSkJmN0RKSlZ5bWRDMnNCeWJjNGtER3hJaUE1YjdyVExDeEdEamd2Mi1LcncyTDBHdl9tdl9YWlRXSEh0ZERXVzRTMEkzbkY3V29CMmFVdW1uV2p3NHNkVmNXdE9aUDU1VGV4ZGVXeVpFVXVJY1dydjIxclA3MkFkeGlvem9SUjB0dlRFZlBlWXJ5NDFCalBpSmk5VkhpUl9fT3pHSUdGZGU1YTRhSzZwWnNMQUlCWkZLSXJGbE1mX1NZ?oc=5","date":"2024-11-19","type":"pipeline","source":"GlobeNewswire","summary":"Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight - GlobeNewswire","headline":"Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxPRkJLQ0l0M05vSXRrTzFvcDl3aXhDRmU4NzVnalVpaGxRQldGSkxtYXZmemY0WkF1MWp0SEVISVR2dlJ6UFhhQ1FBMUM4bVJNcmdUQ3FtQTExejVCOUx1WWo4Wk9zdWhfWHFObEYwZ0pDM0IxUXVDbEFVSWFuOV91QnVIMG1QVXpRZkstLWJrenJiek4wSkVaQS1kTjNsbGJ1UjdKYVpIQUhwVzQ5VUcydThqNVJqNS1zYnkwa3FoVEtudG9xeTRMdWx6LUVhV01adnpFaEhCbXhwY3A3SURhNFBsOWtvamF2OURMc21TN2sxOWs?oc=5","date":"2024-05-07","type":"trial","source":"GlobeNewswire","summary":"Retinitis Pigmentosa Clinical Trial Pipeline Insights Featuring 40+ Companies | DelveInsight - GlobeNewswire","headline":"Retinitis Pigmentosa Clinical Trial Pipeline Insights Featuring 40+ Companies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxPZGNmMXdzWjhjRjBvNmxyanJFazdOX0VBZU5kTTJLUkxSSGxjbFkzbkM0ZkxxNVRmakN4LVRMQzNzbmliVXVHVnhnbzJ1VTdfRWQ2eFMtZWVIQ1ViWTNaTF9TS3VNd28xRndERWRVd1B3MGFIZERFZmNpbWVXTGkxSWZPYnhwX0N5NmxXSzgzSHhhakdHQzBaWHhsSHF1cEhyMUIzTFlCVk85RjdURFp3RmdrRDlqY3IyYWZRcFVMNENzb0dzWWVYeHA0SUJGaUMxV01vbnFn?oc=5","date":"2024-04-02","type":"pipeline","source":"PR Newswire","summary":"Retinitis Pigmentosa Market to Grow Rapidly at a CAGR of 16.8% by 2034 | DelveInsight - PR Newswire","headline":"Retinitis Pigmentosa Market to Grow Rapidly at a CAGR of 16.8% by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOQXJFMllTQnZLbmx1N3F6cEU0U1FZMm5XMEVpN2R5SDhMVGR1RWJOYTU2Rk5YeEhILTh1YTBuWk9rX0lPY3BFOGtUVkJBX3JFRHlYd0JPY0h4bm1TZFFrUXB6YmJ3SFluNTBJQndGU0w2eEhzQWNXSV9fbTBXdEhVRHd5ZTVaNE1SUG5NMlJFVS1SeVJxaDNWSV9NNklfQ0Q3QWtOeHJEeUQ2YnQ1ZFZuZHVWNy1lQQ?oc=5","date":"2023-10-25","type":"regulatory","source":"PharmaTimes","summary":"FDA grants clearance for Endogena’s age-related macular degeneration treatment - PharmaTimes","headline":"FDA grants clearance for Endogena’s age-related macular degeneration treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNN0ZHcWZaaGw1SHZQQ3BBcmlmNjl1Y0VIbm8yNjY5cHNvc1cwRDJFSnpXX0NrS1pELTc1a3ZCMG45bFJiNmhHOFFQdFJCNDRZUDU4YW1jbVFhM09Edko2end3Zm05aHRua0FuaGR2SE5YTXNPMURadGpVS3poVGRfbFNGNk1HMXFReDRHakF4LV9Pc2pmQjAySEhMMmM5SVVucm9XQWoxM1MxZFpOMFZTTjdNRGdNLWNraDJJRkdlR0twYmltSzhKODEtemNsQkU?oc=5","date":"2023-10-24","type":"regulatory","source":"BioWorld News","summary":"Endogena Therapeutics’ candidate for geographic atrophy receives FDA clearance to enter clinic - BioWorld News","headline":"Endogena Therapeutics’ candidate for geographic atrophy receives FDA clearance to enter clinic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxPWWpqeE9ZNUstb3JpekpwZEpHbUV4M2hGTjh5SU5ZWFdYQ1NwdU9vVGFIMnZkamgwYkZxY2RqVGQ3aHFhbTItcWc5U1NiYnMxTkctbnJrek1Ic0hQZmpnQUlZbjZVYXh3aHBiLUpLODk4OGJnU0hDempUbGRUZmktUzdKMWtCUFBwMGxvdkk5dnctc1dseXJBZC1QSDdUZkMwbkI5ZkU0aHJfNE1hU1lRNjk0Ni1VeDl4QW9ZdTgwVHFYR1N3b3R1anFEZnZtZDhqUHFPS2EzcTBRVTQ?oc=5","date":"2023-04-19","type":"deal","source":"businesswire.com","summary":"Enamine and Endogena Therapeutics – a successful, multi-year drug discovery collaboration - businesswire.com","headline":"Enamine and Endogena Therapeutics – a successful, multi-year drug discovery collaboration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxOdE5tS2FEN1k3Ri1USENUbzlQMXlhVlZNWWh5MWdDcFVfRUxLWHN5b1dpcDRLRWFnejZoZ0pzckFGdkNPLTRZS3p4T1pPSWNkXzdxYjB2d0Y1NVg0VXlfYUszcXN1ZFU4YVJ3MFU5U2cyTjc3QS0zZGFVMkl4WHE4RnBtN2pwRUJ1ck5CWTN0cDRlS3ZJRWZKdUZLSDIzMGh2c0Y5S1ZHRFEyUTVmVFhYc19zemZ1TkdkV0tpMjZndFJoREI3cUZYZ1BvUVJLZjFDNjNGZ3M1d3c0cGFqMlZOcE1LMlBpeVNyenJ1Z180cWs0RDhBV2FVY3RxbWlNRHVBdjVhenRLeXpUV2cyNmVwaWtSSnhHckJfdnc?oc=5","date":"2021-12-13","type":"pipeline","source":"PR Newswire","summary":"Rejuveron Increases to Near-majority Stake in Endogena Through Funding $20m to Progress Treatments for Degenerative Diseases of the Eye - PR Newswire","headline":"Rejuveron Increases to Near-majority Stake in Endogena Through Funding $20m to Progress Treatments for Degenerative Dise","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}